Navigation Links
Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
Date:5/31/2012

BOSTONA novel compound has become the first targeted therapy to benefit patients with the most common genetic subtype of lung cancer, an international clinical trial led by scientists at Dana-Farber Cancer Institute and other institutions will report at the annual meeting of the American Society of Clinical Oncology (ASCO) June 1-5 in Chicago.

Pasi A. Jnne, MD, PhD, scientific co-director of Dana-Farber's Belfer Institute for Applied Cancer Science, will present the findings from the randomized phase II study (abstract 7503) on Monday, June 4, 3 p.m. CT, E Hall D2, McCormick Place.

The study involved 87 non-small cell lung cancer (NSCLC) patients whose tumors carry a mutation in the gene KRAS. Such tumors account for about 20 percent of NSCLC cases, but no targeted therapy has proved effective against them in previous clinical research. The drug under investigation, selumetinib, doesn't attack KRAS directly, but interferes with one of its molecular henchmen, a protein called MEK.

Participants in the study all had advanced stages of the disease. They received the standard chemotherapy agent docetaxel in combination with either selumetinib or a placebo.

By many measures the rate and duration of response to treatment, change in tumor size, and proportion of patients alive and showing no signs of advancing disease -- the group receiving selumetinib did significantly better than the other group. Most clinically significant were the improved rate of response to treatment (37 percent compared to 0 percent in the placebo arm) and prolonged progression-free survival (5.3 months compared to 2.1 months in the placebo arm). Although patients in the selumetinib group survived longer, on average, than those in the placebo group 9.4 months compared to 5.2 months the improvement was not considered statistically significant.

"This clinical trial demonstrates that a combination of chemotherapy and selumetinib is significantly
'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Humans Can Sniff Out Old Age in Others, Study Shows
2. Infant Smarts Similar With Different Types of Formula: Study
3. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
4. Cooling Helps Oxygen-Deprived Newborns: Study
5. Immigrant women giving birth in Spain suffer great stress, a study warns
6. Once-Obese Women Still Face Stigma, Study Finds
7. Surly People Tend to Like Fierce Dogs, Study Shows
8. Nordic Walking a Winner for Heart Failure Patients, Study Says
9. Common Painkillers May Help Prevent Skin Cancer: Study
10. Antioxidant shows promise as treatment for certain features of autism, Stanford study finds
11. Tight Blood-Sugar Control Shows Mixed Results for Health of Kidneys: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
(Date:11/27/2014)... Dallas, Texas (PRWEB) November 27, 2014 ... research report on Global Insulin industry. For an ... including definition, classification, application, industry chain structure, industry ... report on global Insulin industry covers information ... manufacturing process, product cost structure and much more. ...
(Date:11/27/2014)... Allowing children to help with chores while ... give children responsibility, ownership, boosts self-esteem, and above all, helps ... the real question is, how do you encourage your children ... a study published by Child Development Journal, there is. The ... on a child’s willingness to lend a hand. , ...
(Date:11/27/2014)... November 27, 2014 RBSEO Services, ... search engine optimization service just at $99. RBSEO ... start-ups cannot afford costly search engine optimization service. ... keeping their affordablity and requirements into consideration. ... but it has not compromised with the service ...
(Date:11/27/2014)... 2014 Ethane Web Technologies, an ISO 9001: ... a 10% Christmas discount on PPC service. The discount will ... offer will begin on 1 December 2014 and remain valid ... offer, a PPC professional working at Ethane Web Technologies says, ... businesses, as this big discount would make the service quite ...
Breaking Medicine News(10 mins):Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:RBSEO Services Announces SEO Services at $99 Only 2Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... team of doctors in Himachal Pradesh have removed an 18 ... was performed Wednesday at a hospital in Kullu, 240 km ... in Mandi district had reported at the hospital with pain ... 90 minutes to remove the hard oval shaped tumour from ...
... findings of a study shed light on a nagging mystery ... contain// considerable pools of free zinc ions. Zinc - a ... regulate neuronal signaling in the brain and spinal cord – ... a mutation affecting a neuronal zinc target, researchers have demonstrated ...
... to the general public as the number of reported infections ... Daily said// Wednesday. ,The latest statistics from the ... to 183,733 this year, up from 144,089 at the end ... 40,667 have developed into AIDS. ,"Health officials attributed ...
... called bivalirudin (Angiomax) that beats the standard combination drug ... heart// attacks. This new blood thinner seems to be ... ,The Results of the ‘Acute Catheterization and ... November issue of the New England Journal of Medicine. ...
... a widely used medication to strengthen fragile, aging bones ... recent study led by Johns Hopkins// rheumatologist Clifton Bingham, ... might be used to treat osteoarthritis after noticing that ... of drugs, not only slowed joint damage in animals, ...
... and adolescents are enjoying the health and social ... observers have noted problems related to// over-competitiveness and ... alarming increases in sport-related injuries in young athletes. ... Sport Medicine is a special Thematic Issue providing ...
Cached Medicine News:Health News:Zinc – A New Key Player In Brain Circuitr 2Health News:Alarming Rise in HIV Cases in China: Report 2Health News:New Anti-Clotting Drug Less Risky For Heart Attack Patients 2Health News:Millions with Arthritis May Benefit from Bone Loss Drug 2Health News:Kids in Sport—Great for Fitness, but Concern About Injurie 2Health News:Kids in Sport—Great for Fitness, but Concern About Injurie 3
(Date:11/26/2014)... 26, 2014  Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... conferences. On Tuesday, December 2, the company ... Jaffray Healthcare Conference.  D. Keith Grossman , President ... the company beginning at 11:30 a.m., Eastern Standard Time ...
(Date:11/26/2014)... Company plc ("Perrigo") (NYSE: PRGO ; TASE), ... today announced the closing of Perrigo,s previously announced registered ... shares at a public offering price of $152.00 per ... purchase up to an additional 888,157 ordinary shares by ... representatives of the several underwriters. Perrigo ...
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon Pharmaceuticals, ... the completion of previously announced concurrent financing transactions ... fees and estimated offering expenses, Lexicon anticipates net ...  The transactions consisted of: , a ... pursuant to a registration statement that has been ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
Cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, 1.5 mm long wedge-shaped, inferior edge with round end, 0.6 mm dual sideports 20 gauge....
Phaco chopper elongated Kuglen style push-pull tip with wedge shaped superior and inferior edges. For bi-directional chopping....
... Floor Plates feature a unique design for ... a CP titanium and .3mm thick for ... for optimal malleability. Universal (left/right) anatomical shape ... out and smooth construction for optimal safety. ...
Medicine Products: